IL6 and ovarian cancer: Thus, the anti-IL-6 antibody siltuximab has been shown to reduce STAT3 activation and angiogenesis in IL-6-producing xenografts of intraperitoneal ovarian cancer and reduces VEGF levels in patients with ovarian cancer [32].